AI Article Synopsis
- A Japanese phase II trial (FACOS) studied the long-term effectiveness of oxaliplatin-based chemotherapy in patients with stage III colon cancer, reporting a five-year overall survival (OS) rate of 91.4%.
- No significant differences were found between the treatment regimens (mFOLFOX6 and CAPOX) in terms of survival rates.
- Long-term effects showed that approximately 21.8% of survivors experienced persistent peripheral sensory neuropathy (PSN) after five years, which may impact their quality of life despite the positive survival outcomes.
Article Abstract
Purpose: We previously reported the first evidence of oncological benefits from a Japanese phase II trial of oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (the FACOS study). We herein report the long-term survival and persistent oxaliplatin-related peripheral sensory neuropathy (PSN) for patients enrolled in this trial.
Methods: Patients were scheduled to receive the mFOLFOX6 or CAPOX regimen in the adjuvant setting. The five-year overall survival (OS) rate and persistent PSN were evaluated.
Results: A total of 130 patients (mFOLFOX6, n = 73; CAPOX, n = 57) were eligible. The 5-year OS rate was 91.4%. No significant difference in the OS rate was observed between regimens (mFOLFOX6, 94.4%; CAPOX, 87.4%; P = 0.25). The incidence of PSN during adjuvant treatment was 55.4% in grade 1 (G1), 30.0% in G2, and 4.6% in G3. No patients showed G3 PSN at 12 months, but G1 or G2 residual PSN after 5 years was observed in 21.8% (G1, 20%; G2, 1.8%).
Conclusions: Updated results from the FACOS study support the benefits of oxaliplatin-based adjuvant chemotherapy in terms of the long-term survival among Japanese patients with stage III colon cancer. However, long-term persistent PSN occurs in about 20% of survivors, counterbalancing the favorable OS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00595-021-02230-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ferulic acid grafted onto chitooligosaccharides attenuates LPS-stimulated in murine macrophages by modulating the NF-κB and MAPK pathways.
Nat Prod Res
November 2024
Department of Biochemistry, Faculty of Biology-Biotechnology, University of Science, Ho Chi Minh City, Vietnam.
Although chitooligosaccharides (COS) improve the drawbacks of chitosan, their biological activities in medical applications have not been highly appreciated. The main approach is to synthesise the COS derivatives in order to improve the biological properties of the COS. In this study, ferulic acid (FA) grafted onto COS (FA-COS) were synthesised and their mechanism of anti-inflammatory activity was investigated in the murine macrophage cells.
View Article and Find Full Text PDFFolic Acid-Chitosan Oligosaccharide Conjugates Decorated Nanodiamond as Potential Carriers for the Oral Delivery of Doxorubicin.
AAPS PharmSciTech
March 2023
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Oral administration of doxorubicin (DOX) is preferred but challenged owing to poor permeability in the gastrointestinal tract (GIT), efflux of P-glycoprotein, short residence time in the intestine, and rapid hydrolysis. Herein, folic acid-chitosan oligosaccharide conjugate (FA-COS)-modified hydroxylated nanodiamond (ND-OH) was designed to enhance the oral bioavailability of DOX. The carboxyl surface of ND was modified into hydroxyl terminal group to increase the colloidal stability of the system under different pH conditions in GIT.
View Article and Find Full Text PDFVariations in management of A3 and A4 cervical spine fractures as designated by the AO Spine Subaxial Injury Classification System.
J Neurosurg Spine
January 2022
11The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.
Objective: Optimal management of A3 and A4 cervical spine fractures, as defined by the AO Spine Subaxial Injury Classification System, remains controversial. The objectives of this study were to determine whether significant management variations exist with respect to 1) fracture location across the upper, middle, and lower subaxial cervical spine and 2) geographic region, experience, or specialty.
Methods: A survey was internationally distributed to 272 AO Spine members across six geographic regions (North America, South America, Europe, Africa, Asia, and the Middle East).
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Surg Today
August 2021
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Article Synopsis
- A Japanese phase II trial (FACOS) studied the long-term effectiveness of oxaliplatin-based chemotherapy in patients with stage III colon cancer, reporting a five-year overall survival (OS) rate of 91.4%.
- No significant differences were found between the treatment regimens (mFOLFOX6 and CAPOX) in terms of survival rates.
- Long-term effects showed that approximately 21.8% of survivors experienced persistent peripheral sensory neuropathy (PSN) after five years, which may impact their quality of life despite the positive survival outcomes.
Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Int J Clin Oncol
December 2020
Department of Surgery Saitama Medical center, Saitama Medical University, Saitama, Japan.
Background: Chemotherapy with oxaliplatin is known to induce sinusoidal obstruction syndrome (SOS). In a previous single-center study, we reported that oxaliplatin-induced increase in splenic volume (SV) is strongly indicative of SOS, and that this increase in SV persisted for > 1 year after completing chemotherapy. The aim of this study was to confirm the oxaliplatin-induced SV change in a multicenter study in patients with stage III colon cancer in Japan.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!